Not Yet RecruitingNot Applicable

Long-Acting Injectable HIV PrEP PROs

United States128 participantsStarted 2026-01-15

Plain-language summary

The goal of this observational study is to learn about the real world effectiveness, patient satisfaction and clinical outcomes of LAI PrEP with lenacapavir (LEN) versus cabotegravir (CAB) through surveys and interviews. Participants receiving or initiating LAI PrEP part of their regular medical care will complete surveys and interviews at three study visits over the course of 12 months.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults aged 18 and older
✓. Deemed eligible for HIV PrEP per healthcare provider
✓. Receiving or initiating LAI PrEP, defined as:
✓. Current use of CAB or LEN LAI PrEP at study entry
✓. Initiation of either CAB or LEN LAI PrEP within 30 days of study enrollment
✓. Receiving PrEP services in Louisville, KY
✓. Able to provide informed consent and complete study assessments

Exclusion criteria

✕. HIV diagnosis prior to enrollment
✕. Currently on oral PrEP with no plans to switch to LAI PrEP
✕. Hypersensitivities to LEN or CAB
✕. Pregnant or planning to become pregnant
✕. PI discretion

What they're measuring

LAI-SQ-6 Survey, Long-Acting Injectable Satisfaction Questionnaire

Timeframe: Time of Enrollment, 6 months, 12 months

Trial details

NCT IDNCT07379658

SponsorAnupama Raghuram MD

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-01

Contact for this trial

NIDI Research Clinic

502-861-4646 SystemNIDI@nortonhealthcare.org

View on ClinicalTrials.gov More HIV Pre-exposure Prophylaxis trials